Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes
NCT ID: NCT01234727
Last Updated: 2011-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
501 participants
OBSERVATIONAL
2010-12-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Blood Glucose Monitoring Systems
NCT01909687
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
NCT00401622
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
NCT01237301
An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes
NCT02082184
Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes
NCT01460459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetes
Patients with Type 1 or Type 2 diabetes requiring insulin.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 75 years.
* Patients with stable blood glucose in judgment of the investigator.
* Subjects receive intensive insulin therapy (Multiple Daily Injection defined as at least two insulin injections per day)
* Patients perform blood glucose self measurements on a routine basis
* Patients must have experience in self measurement blood glucose for at least 6 months.
Exclusion Criteria
* Patient has been diagnosed with progressive / serious diseases that in judgment of the investigator preclude successful completion of the observational period.
* Lack of compliance or other justifications that, in the discretion of the investigator, precludes satisfactory participation in the study.
* Subject without legal capacity.
* Blood donation within the last 30 days.
* Known pregnancy.
* Subject has already participated in the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ikfe-CRO GmbH
INDUSTRY
Abbott Diabetes Care
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zentrum für Diabetes und Gefäßerkrankungen
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joe Bugler
Role: STUDY_DIRECTOR
Abbott Diabetes Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zentrum für Diabetes und Gefäßerkrankungen
Münster, , Germany
Diabetes Zentrum Neuwied
Neuwied, , Germany
Radboud University Nijmegen Centre
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADC-MKG-FSL-10008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.